奎硫平和奋乃静治疗精神分裂症老年患者的对照研究

A control study of treating elderly patients with schizophrenia with quetiapine or perphenazine

目的 对比奎硫平与奋乃静治疗精神分裂症的疗效和安全性。方法 对 130例精神分裂症老年患者分别给予奎硫平、奋乃静治疗 ,其中奎硫平组 6 6例 ,剂量为 (15 0 0± 6 3)mg/d ;奋乃静组 6 4例 ,剂量为 (16 0± 3 4 )mg/d ;疗程共 12周。采用阳性和阴性症状量表 (PANSS)、临床疗效总评量表 (CGI)及治疗中需处理的副反应量表 (TESS) ,在治疗前及治疗后第 1,2 ,4 ,8,12周末分别评定疗效和副反应。结果 (1)两组治疗后与治疗前的PANSS评分比较 ,差异有显著性或非常显著性 (P <0 0 5或P <0 0 1)。 (2 )两组间从治疗第 1周末起 ,各时点PANSS减分率差异有显著性或非常显著性(P <0 0 5或P <0 0 1)。 (3)两组间CGI评分差异无显著性 (P >0 0 5 )。奎硫平和奋乃静的有效率分别为 6 7%和 6 6 % ,疗效的差异无显著性 (P >0 0 5 )。奎硫平、奋乃静的有效剂量范围分别为 10 0～ 2 5 0mg/d ,10～ 2 4mg/d。 (4)TESS评定显示 ,奎硫平组副反应少于奋乃静组。治疗期间奋乃静组合用安坦39例 (6 1% ) ,奎硫平组 2 3例 (35 % ) ,差异有非常显著性 (P <0 0 1)。结论 奎硫平治疗精神分裂症疗效好、起效快、不良反应较奋乃静轻微。

Object The purpose of this study was to assess the efficacy and safety of quetiapine and perphenazine Methods One hundred and thirty elderly patents with schizophrenia were recruited in the study, with 66 treated with quetiapine [ (150 0±6 3) mg/d] and 64 with perphenazine [(16 0±3 4) mg/d] The therapy persisted 12 weeks The Positive and Negative Syndrome Scale (PANSS), Clinical Global Impressions Scale (CGI) and Treatment Emergent Symptoms Scale (TESS) was used to measure therapeutic efficacy and side effects Results (1) The PANSS scores in both groups decreased significantly after treatment ( P <0 05- P <0 01) (2)The decreasing radio of PANSS score between two groups was significant different at any time point from the first weekend after treatment ( P <0 05- P <0 01) (3) CGI score was not significantly different between groups ( P >0 05) The rate of improvement was similar in quetiapine group and perphenazine group (67% vs 66%, P >0 05) The efficient dosage range of quetiapine was 100-250 mg per day and perphenazine 10-24 mg per day (4) TESS showed quetiapine had less side effects than perphenazine ( P <0 01) Conclusion Quetiapine is of good efficacy, rapid action, high safety and less side effects in treating elderly patients with schizophrenia